Amphotericin B (Amphotericin)

01/01/2015 - "Amphotericin B (AmB) is a highly efficacious therapeutic for invasive fungal infections and protozoal diseases. "
09/01/2004 - "Encapsulated amphotericin was highly effective against infection causing a reduction of 88.8% and 87.2% in the early stage of infection (day 32 p.i.) and of 66.7% and 54% in a later stage of infection (day 135 p.i.) in liver and spleen parasite load respectively, compared with untreated animals, whereas free amphotericin was inactive. "
05/01/1999 - "Although amphotericin B desoxycholate is considered the most effective treatment for disseminated Paracoccidioides brasiliensis infections, little is known about the efficacy of lipid-based formulations of amphotericin B in this infection. "
11/01/1989 - "Amphotericin B is the most effective agent for the majority of systemic fungal infections but often causes toxicity, and specific dosage guidelines for amphotericin B in pediatric patients are lacking. "
01/01/1982 - "The most commonly involved joint has been the knee; in such cases, amphotericin B has been effective in controlling the infection. "

11/01/1996 - "Surgical intervention and concomitant use of amphotericin-B for a month resulted in complete remission of the aspergillosis. "
03/16/1985 - "In conjunction with high dose amphotericin-B therapy complete resolution of aspergillosis was achieved in two cases, paralleled by slow recovery of bone marrow function, whereas in the third case only a partial remission was possible together with transient amelioration of granulopoiesis. "
07/01/2015 - "Although amphotericin B-azole combination therapy has traditionally been questioned due to potential antagonistic interactions, it is often used successfully to treat refractory invasive aspergillosis. "
05/01/2005 - "In clinical trials it demonstrated superior efficacy in addition to a survival benefit when compared with the then current treatment standard, amphotericin B, for primary treatment of invasive aspergillosis. "
11/15/2005 - "This study highlights the limited efficacy of salvage antifungal therapy, including therapy with lipid formulations of amphotericin B, and demonstrates the importance of effective initial therapy in invasive aspergillosis."

01/15/2012 - "Amphotericin B (AmB), is a highly effective antileishmanial agent used as first-line treatment in different formulations in visceral leishmaniasis endemic areas of Bihar, India. "
11/01/1999 - "This patient never received highly active antiretroviral treatment and the visceral leishmaniasis could not be cured even with liposomal amphotericin. "
09/01/1992 - "Because lipid particles are phagocytized by the reticuloendothelial system, lipid-associated amphotericin B should be concentrated in infected macrophages and be very effective against visceral leishmaniasis. "
08/01/2009 - "This formulation has overcome amphotericin B's significant physicochemical barriers to absorption and holds promise for the development of a self-administered oral therapy for the treatment of visceral leishmaniasis."
05/01/2009 - "Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis."

06/01/2003 - "Gargling with amphotericin B was effective in most asthmatic patients with candidiasis. "
04/01/1989 - "Local application of amphotericin B and donor leukocytic mass was found the most effective in the combined treatment of candidiasis of the esophagus."
05/01/2003 - "In a neutropenic murine model of disseminated candidiasis, kidney colony-forming unit determination revealed dose-dependent efficacy for the polymeric micelle/AmB formulation, which was not significantly different from that of Fungizone at doses of 0.2, 0.3, and 0.6 mg/kg (p = 0.7). "
12/01/2002 - "Intravenous amphotericin B has been found to be effective in azole-refractory candidiasis and is well tolerated. "
06/01/2000 - "Mild heating of amphotericin B-desoxycholate: effects on ultrastructure, in vitro activity and toxicity, and therapeutic efficacy in severe candidiasis in leukopenic mice."

07/15/2010 - "It is generally acknowledged that amphotericin B is the most effective treatment for cryptococcal meningitis. "
03/01/1990 - "Although the introduction of amphotericin B has greatly improved the prognosis of patients with cryptococcal meningitis, 30 years of experience have revealed important clinical limitations, including modest efficacy, nephrotoxicity, other clinically significant toxicities, and the inconvenience of intravenous dosing. "
01/01/2011 - "Efficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice."
06/26/1993 - "[Efficacy of liposomal amphotericin in the treatment of cryptococcal meningitis in a cirrhotic patient with intolerance to conventional amphotericin]."
01/01/1963 - "The improved prognosis of cryptococcal meningitis with amphotericin B therapy."